COMMUNIQUÉS West-GlobeNewswire

Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
22/10/2026
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Ignite Proteomics Enters Breast Cancer Research Collaboration with Leading Cancer Center
22/10/2026
Research Will Apply Ignite's RPPA-Based Proteomic Test to Study Treatment Response and Resistance GOLDEN, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ignite Proteomics, Inc. (“Ignite” or the “Company”), a precision [...]
Annovis to Attend the CTAD 2026 with Three Presentations
22/10/2026
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
22/10/2026
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to receive $45 million in upfront and near-term payments, as part of [...]
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
22/10/2026
CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion ® and the AYON Body [...]
Rgenta Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Trial Design for RGT-61159 in Patients with Adenoid Cystic Carcinoma (ACC)
22/10/2026
Phase 3 trial alignment paves path toward New Drug Application and potential approval of RGT-61159, an oral small molecule targeting the MYB oncogene Prior preliminary data in patients treated at or below recommended [...]
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
22/10/2026
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data [...]
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
22/10/2026
PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026
22/10/2026
LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30 [...]
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
22/10/2026
PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, [...]
Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection
22/10/2026
kt-5000AI delivers potent and selective ATR inhibition, CNS-oriented properties and preclinical tumour-growth control, advancing a capital-efficient drug discovery program toward candidate selection VANCOUVER, British [...]
KFSH Expands Capacity for Complex Care by Redesigning the Emergency Patient Journey
22/10/2026
RIYADH, Saudi Arabia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has expanded capacity for complex care by redesigning the emergency patient journey, meeting rising [...]
Levicept Announces Attendance at Major Healthcare Conferences in Q4
22/10/2026
SANDWICH, United Kingdom, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a clinical-stage biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), is pleased to [...]
Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy
22/10/2026
Submission marks an important milestone towards bringing a new treatment option to patients with DMD in South Korea. Vamorolone has already received South Korean Orphan Drug Designation (ODD) and Global Innovative [...]
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
22/10/2026
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological [...]
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
22/10/2026
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological [...]
Persica Pharmaceuticals presents antibiotic exposure-response analysis at the International Society of Pain & Neuroscience (ISPN) Annual Conference
22/10/2026
London, UK, 22 October 2026 - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), today [...]
Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance
22/10/2026
Year-to-date total sales growth of 24.6% at CER 1 , or 23.0% as reported, with the core portfolio 2 achieving sales growth of 24.2% 1 Further upgraded FY 2026 financial guidance: total sales growth around 23.0% at CER ( [...]
Ipsen réalise une croissance remarquable des ventes au cours des neuf premiers mois de 2026 et relève à nouveau ses prévisions pour l’exercice en cours
22/10/2026
Croissance du chiffre d’affaires du Groupe de 24,6 % à taux de change constant 1 (TCC) au cours des neuf premiers mois de l’année 2026 ou 23,0 % en données publiées, avec une croissance du portefeuille stratégique 2 de [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum